Ontology type: schema:ScholarlyArticle Open Access: True
2014-10-14
AUTHORSChrisann Kyi, Richard D Carvajal, Jedd D Wolchok, Michael A Postow
ABSTRACTCytotoxic T-Lymphocyte Antigen 4 (CTLA-4), an immune-checkpoint receptor and regulator of T-cell activation, has become an important therapeutic target for immunotherapy in cancer and autoimmune diseases. To date, clinical trials involving cancer immunotherapies, such checkpoint blocking antibodies directed at CTLA-4 (ipilimumab), have excluded patients with underlying autoimmune disease given concern for potential triggering of autoimmune exacerbations. We present the first known cases to our knowledge of two patients with active autoimmune diseases who received ipilimumab. In this limited clinical experience, no serious exacerbations of underlying autoimmunity have yet been observed, and one patient benefited from ipilimumab. These cases advocate for further investigation of the safety of cancer immunotherapies in cancer patients with underlying autoimmune conditions in carefully designed clinical trials with cautious monitoring. More... »
PAGES35
http://scigraph.springernature.com/pub.10.1186/s40425-014-0035-z
DOIhttp://dx.doi.org/10.1186/s40425-014-0035-z
DIMENSIONShttps://app.dimensions.ai/details/publication/pub.1011546195
PUBMEDhttps://www.ncbi.nlm.nih.gov/pubmed/25349698
JSON-LD is the canonical representation for SciGraph data.
TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT
[
{
"@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json",
"about": [
{
"id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11",
"inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/",
"name": "Medical and Health Sciences",
"type": "DefinedTerm"
},
{
"id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1107",
"inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/",
"name": "Immunology",
"type": "DefinedTerm"
}
],
"author": [
{
"affiliation": {
"alternateName": "New York-Presbyterian Hospital - Weill Cornell Medical College, 525 E 68th Street, 10065, New York, NY, USA",
"id": "http://www.grid.ac/institutes/grid.5386.8",
"name": [
"New York-Presbyterian Hospital - Weill Cornell Medical College, 525 E 68th Street, 10065, New York, NY, USA"
],
"type": "Organization"
},
"familyName": "Kyi",
"givenName": "Chrisann",
"id": "sg:person.01070606664.05",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01070606664.05"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Weill Cornell Medical College, 525 E 68th Street, 10065, New York, NY, USA",
"id": "http://www.grid.ac/institutes/grid.5386.8",
"name": [
"Melanoma and Immunotherapeutics Oncology Service, Memorial Sloan Kettering Cancer Center, 300 East 66th Street, 10065, New York, NY, USA",
"Weill Cornell Medical College, 525 E 68th Street, 10065, New York, NY, USA"
],
"type": "Organization"
},
"familyName": "Carvajal",
"givenName": "Richard D",
"id": "sg:person.0726366600.25",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0726366600.25"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Weill Cornell Medical College, 525 E 68th Street, 10065, New York, NY, USA",
"id": "http://www.grid.ac/institutes/grid.5386.8",
"name": [
"Melanoma and Immunotherapeutics Oncology Service, Memorial Sloan Kettering Cancer Center, 300 East 66th Street, 10065, New York, NY, USA",
"Weill Cornell Medical College, 525 E 68th Street, 10065, New York, NY, USA"
],
"type": "Organization"
},
"familyName": "Wolchok",
"givenName": "Jedd D",
"id": "sg:person.0645565266.33",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0645565266.33"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Weill Cornell Medical College, 525 E 68th Street, 10065, New York, NY, USA",
"id": "http://www.grid.ac/institutes/grid.5386.8",
"name": [
"Melanoma and Immunotherapeutics Oncology Service, Memorial Sloan Kettering Cancer Center, 300 East 66th Street, 10065, New York, NY, USA",
"Weill Cornell Medical College, 525 E 68th Street, 10065, New York, NY, USA"
],
"type": "Organization"
},
"familyName": "Postow",
"givenName": "Michael A",
"id": "sg:person.0663446543.06",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0663446543.06"
],
"type": "Person"
}
],
"datePublished": "2014-10-14",
"datePublishedReg": "2014-10-14",
"description": "Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4), an immune-checkpoint receptor and regulator of T-cell activation, has become an important therapeutic target for immunotherapy in cancer and autoimmune diseases. To date, clinical trials involving cancer immunotherapies, such checkpoint blocking antibodies directed at CTLA-4 (ipilimumab), have excluded patients with underlying autoimmune disease given concern for potential triggering of autoimmune exacerbations. We present the first known cases to our knowledge of two patients with active autoimmune diseases who received ipilimumab. In this limited clinical experience, no serious exacerbations of underlying autoimmunity have yet been observed, and one patient benefited from ipilimumab. These cases advocate for further investigation of the safety of cancer immunotherapies in cancer patients with underlying autoimmune conditions in carefully designed clinical trials with cautious monitoring.",
"genre": "article",
"id": "sg:pub.10.1186/s40425-014-0035-z",
"isAccessibleForFree": true,
"isFundedItemOf": [
{
"id": "sg:grant.2438793",
"type": "MonetaryGrant"
},
{
"id": "sg:grant.2622404",
"type": "MonetaryGrant"
},
{
"id": "sg:grant.2682501",
"type": "MonetaryGrant"
}
],
"isPartOf": [
{
"id": "sg:journal.1049249",
"issn": [
"2051-1426"
],
"name": "Journal for ImmunoTherapy of Cancer",
"publisher": "BMJ",
"type": "Periodical"
},
{
"issueNumber": "1",
"type": "PublicationIssue"
},
{
"type": "PublicationVolume",
"volumeNumber": "2"
}
],
"keywords": [
"autoimmune diseases",
"cancer immunotherapy",
"clinical trials",
"cytotoxic T-lymphocyte antigen-4",
"T-lymphocyte antigen-4",
"active autoimmune disease",
"underlying autoimmune disease",
"immune checkpoint receptors",
"limited clinical experience",
"T cell activation",
"important therapeutic target",
"autoimmune exacerbation",
"serious exacerbations",
"autoimmune conditions",
"antigen-4",
"CTLA-4",
"cancer patients",
"cautious monitoring",
"therapeutic target",
"clinical experience",
"patients",
"ipilimumab",
"immunotherapy",
"disease",
"exacerbation",
"further investigation",
"trials",
"autoimmunity",
"melanoma",
"cancer",
"antibodies",
"receptors",
"cases",
"activation",
"potential triggering",
"such checkpoints",
"safety",
"target",
"regulator",
"checkpoint",
"date",
"triggering",
"experience",
"monitoring",
"concern",
"knowledge",
"investigation",
"conditions"
],
"name": "Ipilimumab in patients with melanoma and autoimmune disease",
"pagination": "35",
"productId": [
{
"name": "dimensions_id",
"type": "PropertyValue",
"value": [
"pub.1011546195"
]
},
{
"name": "doi",
"type": "PropertyValue",
"value": [
"10.1186/s40425-014-0035-z"
]
},
{
"name": "pubmed_id",
"type": "PropertyValue",
"value": [
"25349698"
]
}
],
"sameAs": [
"https://doi.org/10.1186/s40425-014-0035-z",
"https://app.dimensions.ai/details/publication/pub.1011546195"
],
"sdDataset": "articles",
"sdDatePublished": "2022-08-04T17:03",
"sdLicense": "https://scigraph.springernature.com/explorer/license/",
"sdPublisher": {
"name": "Springer Nature - SN SciGraph project",
"type": "Organization"
},
"sdSource": "s3://com-springernature-scigraph/baseset/20220804/entities/gbq_results/article/article_641.jsonl",
"type": "ScholarlyArticle",
"url": "https://doi.org/10.1186/s40425-014-0035-z"
}
]
Download the RDF metadata as: json-ld nt turtle xml License info
JSON-LD is a popular format for linked data which is fully compatible with JSON.
curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/s40425-014-0035-z'
N-Triples is a line-based linked data format ideal for batch operations.
curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/s40425-014-0035-z'
Turtle is a human-readable linked data format.
curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/s40425-014-0035-z'
RDF/XML is a standard XML format for linked data.
curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/s40425-014-0035-z'
This table displays all metadata directly associated to this object as RDF triples.
138 TRIPLES
20 PREDICATES
73 URIs
65 LITERALS
7 BLANK NODES
Subject | Predicate | Object | |
---|---|---|---|
1 | sg:pub.10.1186/s40425-014-0035-z | schema:about | anzsrc-for:11 |
2 | ″ | ″ | anzsrc-for:1107 |
3 | ″ | schema:author | N62b3f09aeef443258e41641cef92d2bf |
4 | ″ | schema:datePublished | 2014-10-14 |
5 | ″ | schema:datePublishedReg | 2014-10-14 |
6 | ″ | schema:description | Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4), an immune-checkpoint receptor and regulator of T-cell activation, has become an important therapeutic target for immunotherapy in cancer and autoimmune diseases. To date, clinical trials involving cancer immunotherapies, such checkpoint blocking antibodies directed at CTLA-4 (ipilimumab), have excluded patients with underlying autoimmune disease given concern for potential triggering of autoimmune exacerbations. We present the first known cases to our knowledge of two patients with active autoimmune diseases who received ipilimumab. In this limited clinical experience, no serious exacerbations of underlying autoimmunity have yet been observed, and one patient benefited from ipilimumab. These cases advocate for further investigation of the safety of cancer immunotherapies in cancer patients with underlying autoimmune conditions in carefully designed clinical trials with cautious monitoring. |
7 | ″ | schema:genre | article |
8 | ″ | schema:isAccessibleForFree | true |
9 | ″ | schema:isPartOf | N56a406cbbfb14e638d31bac9063e157d |
10 | ″ | ″ | N5710c67e4d0f496aa60cad03c6d74200 |
11 | ″ | ″ | sg:journal.1049249 |
12 | ″ | schema:keywords | CTLA-4 |
13 | ″ | ″ | T cell activation |
14 | ″ | ″ | T-lymphocyte antigen-4 |
15 | ″ | ″ | activation |
16 | ″ | ″ | active autoimmune disease |
17 | ″ | ″ | antibodies |
18 | ″ | ″ | antigen-4 |
19 | ″ | ″ | autoimmune conditions |
20 | ″ | ″ | autoimmune diseases |
21 | ″ | ″ | autoimmune exacerbation |
22 | ″ | ″ | autoimmunity |
23 | ″ | ″ | cancer |
24 | ″ | ″ | cancer immunotherapy |
25 | ″ | ″ | cancer patients |
26 | ″ | ″ | cases |
27 | ″ | ″ | cautious monitoring |
28 | ″ | ″ | checkpoint |
29 | ″ | ″ | clinical experience |
30 | ″ | ″ | clinical trials |
31 | ″ | ″ | concern |
32 | ″ | ″ | conditions |
33 | ″ | ″ | cytotoxic T-lymphocyte antigen-4 |
34 | ″ | ″ | date |
35 | ″ | ″ | disease |
36 | ″ | ″ | exacerbation |
37 | ″ | ″ | experience |
38 | ″ | ″ | further investigation |
39 | ″ | ″ | immune checkpoint receptors |
40 | ″ | ″ | immunotherapy |
41 | ″ | ″ | important therapeutic target |
42 | ″ | ″ | investigation |
43 | ″ | ″ | ipilimumab |
44 | ″ | ″ | knowledge |
45 | ″ | ″ | limited clinical experience |
46 | ″ | ″ | melanoma |
47 | ″ | ″ | monitoring |
48 | ″ | ″ | patients |
49 | ″ | ″ | potential triggering |
50 | ″ | ″ | receptors |
51 | ″ | ″ | regulator |
52 | ″ | ″ | safety |
53 | ″ | ″ | serious exacerbations |
54 | ″ | ″ | such checkpoints |
55 | ″ | ″ | target |
56 | ″ | ″ | therapeutic target |
57 | ″ | ″ | trials |
58 | ″ | ″ | triggering |
59 | ″ | ″ | underlying autoimmune disease |
60 | ″ | schema:name | Ipilimumab in patients with melanoma and autoimmune disease |
61 | ″ | schema:pagination | 35 |
62 | ″ | schema:productId | N5495fbea437c42909252a2aa89ef0a77 |
63 | ″ | ″ | N7079919111794cb185fa929b96257bfa |
64 | ″ | ″ | Nc0268ac262a4400f89ea6ea45d993e1f |
65 | ″ | schema:sameAs | https://app.dimensions.ai/details/publication/pub.1011546195 |
66 | ″ | ″ | https://doi.org/10.1186/s40425-014-0035-z |
67 | ″ | schema:sdDatePublished | 2022-08-04T17:03 |
68 | ″ | schema:sdLicense | https://scigraph.springernature.com/explorer/license/ |
69 | ″ | schema:sdPublisher | N0810ed4aefbf4f88ae49b9ada0538554 |
70 | ″ | schema:url | https://doi.org/10.1186/s40425-014-0035-z |
71 | ″ | sgo:license | sg:explorer/license/ |
72 | ″ | sgo:sdDataset | articles |
73 | ″ | rdf:type | schema:ScholarlyArticle |
74 | N0810ed4aefbf4f88ae49b9ada0538554 | schema:name | Springer Nature - SN SciGraph project |
75 | ″ | rdf:type | schema:Organization |
76 | N5495fbea437c42909252a2aa89ef0a77 | schema:name | dimensions_id |
77 | ″ | schema:value | pub.1011546195 |
78 | ″ | rdf:type | schema:PropertyValue |
79 | N56a406cbbfb14e638d31bac9063e157d | schema:volumeNumber | 2 |
80 | ″ | rdf:type | schema:PublicationVolume |
81 | N5710c67e4d0f496aa60cad03c6d74200 | schema:issueNumber | 1 |
82 | ″ | rdf:type | schema:PublicationIssue |
83 | N62b3f09aeef443258e41641cef92d2bf | rdf:first | sg:person.01070606664.05 |
84 | ″ | rdf:rest | N8bd70764923c4fb7aa03b42ddc45ac79 |
85 | N7079919111794cb185fa929b96257bfa | schema:name | pubmed_id |
86 | ″ | schema:value | 25349698 |
87 | ″ | rdf:type | schema:PropertyValue |
88 | N85f30690a40e4a67866f8a873957291f | rdf:first | sg:person.0663446543.06 |
89 | ″ | rdf:rest | rdf:nil |
90 | N8bd70764923c4fb7aa03b42ddc45ac79 | rdf:first | sg:person.0726366600.25 |
91 | ″ | rdf:rest | Nc7724a0b1fae4961bb87ece2f51e4f6b |
92 | Nc0268ac262a4400f89ea6ea45d993e1f | schema:name | doi |
93 | ″ | schema:value | 10.1186/s40425-014-0035-z |
94 | ″ | rdf:type | schema:PropertyValue |
95 | Nc7724a0b1fae4961bb87ece2f51e4f6b | rdf:first | sg:person.0645565266.33 |
96 | ″ | rdf:rest | N85f30690a40e4a67866f8a873957291f |
97 | anzsrc-for:11 | schema:inDefinedTermSet | anzsrc-for: |
98 | ″ | schema:name | Medical and Health Sciences |
99 | ″ | rdf:type | schema:DefinedTerm |
100 | anzsrc-for:1107 | schema:inDefinedTermSet | anzsrc-for: |
101 | ″ | schema:name | Immunology |
102 | ″ | rdf:type | schema:DefinedTerm |
103 | sg:grant.2438793 | http://pending.schema.org/fundedItem | sg:pub.10.1186/s40425-014-0035-z |
104 | ″ | rdf:type | schema:MonetaryGrant |
105 | sg:grant.2622404 | http://pending.schema.org/fundedItem | sg:pub.10.1186/s40425-014-0035-z |
106 | ″ | rdf:type | schema:MonetaryGrant |
107 | sg:grant.2682501 | http://pending.schema.org/fundedItem | sg:pub.10.1186/s40425-014-0035-z |
108 | ″ | rdf:type | schema:MonetaryGrant |
109 | sg:journal.1049249 | schema:issn | 2051-1426 |
110 | ″ | schema:name | Journal for ImmunoTherapy of Cancer |
111 | ″ | schema:publisher | BMJ |
112 | ″ | rdf:type | schema:Periodical |
113 | sg:person.01070606664.05 | schema:affiliation | grid-institutes:grid.5386.8 |
114 | ″ | schema:familyName | Kyi |
115 | ″ | schema:givenName | Chrisann |
116 | ″ | schema:sameAs | https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01070606664.05 |
117 | ″ | rdf:type | schema:Person |
118 | sg:person.0645565266.33 | schema:affiliation | grid-institutes:grid.5386.8 |
119 | ″ | schema:familyName | Wolchok |
120 | ″ | schema:givenName | Jedd D |
121 | ″ | schema:sameAs | https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0645565266.33 |
122 | ″ | rdf:type | schema:Person |
123 | sg:person.0663446543.06 | schema:affiliation | grid-institutes:grid.5386.8 |
124 | ″ | schema:familyName | Postow |
125 | ″ | schema:givenName | Michael A |
126 | ″ | schema:sameAs | https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0663446543.06 |
127 | ″ | rdf:type | schema:Person |
128 | sg:person.0726366600.25 | schema:affiliation | grid-institutes:grid.5386.8 |
129 | ″ | schema:familyName | Carvajal |
130 | ″ | schema:givenName | Richard D |
131 | ″ | schema:sameAs | https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0726366600.25 |
132 | ″ | rdf:type | schema:Person |
133 | grid-institutes:grid.5386.8 | schema:alternateName | New York-Presbyterian Hospital - Weill Cornell Medical College, 525 E 68th Street, 10065, New York, NY, USA |
134 | ″ | ″ | Weill Cornell Medical College, 525 E 68th Street, 10065, New York, NY, USA |
135 | ″ | schema:name | Melanoma and Immunotherapeutics Oncology Service, Memorial Sloan Kettering Cancer Center, 300 East 66th Street, 10065, New York, NY, USA |
136 | ″ | ″ | New York-Presbyterian Hospital - Weill Cornell Medical College, 525 E 68th Street, 10065, New York, NY, USA |
137 | ″ | ″ | Weill Cornell Medical College, 525 E 68th Street, 10065, New York, NY, USA |
138 | ″ | rdf:type | schema:Organization |